Increasing the dose of Ocrevus (ocrelizumab) by two- or threefold, depending on a person’s weight, did not provide additional benefit in slowing disability progression compared with the standard regimen in […]
The post ECTRIMS 2025: Standard Ocrevus dose holds up in PPMS appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com